Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in solid tumors.
- Mechanism
- Curator reviewed
DMPEN (4,o-demethylpenclomedine) is the highly reactive principal alkylating metabolite of Penclomedine (PEN), a multichlorinated alpha-picoline derivative. DM-PEN’s proposed mechanism of action begins with activation by free radical formation in the liver, where it is then transported to tumor cells via the circulation system. The free radical moiety forms an adduct with DNA, and interstrand crosslinking occurs through the 5-chloro moiety. The 5-chloro moiety is then activated by keto-enol tautomerism, producing the alkylating group, an alpha-haloketo function.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Formula / weight
- C7H4Cl5NO2 · 311.36 g/mol (avg)
- Also known as
- 4-Demethylpenclomedine · 4-Dm-pen · 4-Dmpen · DM-PEN · DMPEN
- Code names
- NSC-682691
Resolves to
GUYGGZGIKZIRFO-UHFFFAOYSA-NSMILES[H]N1C(OC)=C(Cl)C(=O)C(Cl)=C1C(Cl)(Cl)ClWhat you can answer from here — as of March 06, 2025
Which companies are running trials of 4-O-Demethylpenclomedine, in which indications and phases, and which of those programs are still active?